Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
ImaRx Therapeutics, Inc. (NASDAQ: IMRX) Delayed: 4.44 +0.03 (0.68%)
Previous Close $4.41    52 Week High $0.04 
Open $4.39    52 Week Low $0.00 
Day High $4.69    P/E N/A 
Day Low $4.37    EPS $-0.09 
Volume 1,070,551       

TEVA PHARMACEUTICAL INDUSTRIES (NYSE: TEVA) Delayed: 32.20 +0.72 (2.29%)
Previous Close $31.48    52 Week High $66.55 
Open $31.37    52 Week Low $37.82 
Day High $32.39    P/E N/A 
Day Low $31.28    EPS $0.00 
Volume 6,111,090       

TEVA PHARMACEUTICAL INDUSTRIES (NYSE: TEVA) Delayed: 32.20 +0.72 (2.29%)
Previous Close $31.48    52 Week High $66.55 
Open $31.37    52 Week Low $37.82 
Day High $32.39    P/E N/A 
Day Low $31.28    EPS $0.00 
Volume 6,111,090